Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer

Objective(s): In the treatment of castration-resistant prostate cancer (CRPC) with bone metastases, radium-223 dichloride (Ra-223) is the only bone-targeted drug that shows survival benefits. Completing six courses of Ra-223 treatment is thought to be associated with better patient survival, but thi...

Descrición completa

Detalles Bibliográficos

Principais autores:	Kazuya Takeda, Yoshihide Kawasaki, Toru Sakayauchi, Chiaki Takahashi, Yu Katagiri, Takaya Tanabe, Yojiro Ishikawa, Keisuke Fujimoto, Masaki Kubozono, Maiko Kozumi, Keiko Abe, Kakutaro Narazaki, Shun Tasaka, Rei Umezawa, Takaya Yamamoto, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, So Omata, Akihiro Ito, Keiichi Jingu
Formato:	Artigo
Idioma:	Inglês
Publicado:	Mashhad University of Medical Sciences 2023-01-01
Series:	Asia Oceania Journal of Nuclear Medicine and Biology
Assuntos:	radium-223 dichloride bone metastasis castration-resistant prostate cancer radioisotope therapy
Acceso en liña:	https://aojnmb.mums.ac.ir/article_21211_d0ff0d39bcc092ec6d253a3083560d09.pdf
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!